Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.

Expert Opinion on Pharmacotherapy
Eugenia Negredo, Bonaventura Clotet

Abstract

HIV eradication is not feasible and lifelong treatment is warranted to manage HIV infection. In this scenario, the advent of single-tablet, once-daily, fixed-dose co-formulations is important for reducing pill burden and maximize long-term drug adherence. Cobicistat-boosted darunavir along with emtricitabine and tenofovir alafenamide co-formulation (DRV/c/FTC/TAF or the trade name Symtuza®) is the first marketed protease inhibitor-based fixed-dose combination regimen for the treatment of HIV infection. It was approved in late 2017 by the European Medical Agency both for naïve patients and treatment-experienced patients with viral suppression. Areas covered: PubMed, ClinicalTrials.gov and presentations at scientific meetings were searched with the terms 'darunavir/cobicistat' and 'tenofovir alafenamide and emtricitabine' for clinical trials either conducted to date or ongoing as well as a review of abstracts from major HIV/AIDS and infectious diseases conferences from 2015 to up to date. Expert opinion: DRV/c/FTC/TAF is a novel unique antiretroviral drug co-formulation that exhibits a convenient dosing, satisfactory safety profile, and high antiviral efficacy, even in patients harboring viruses with resistance to antivirals othe...Continue Reading

References

Nov 8, 2013·The New England Journal of Medicine·Sharon L WalmsleyUNKNOWN SINGLE Investigators
Nov 28, 2015·Expert Opinion on Pharmacotherapy·Amedeo CapettiGiuliano Rizzardini
Mar 8, 2016·The Journal of Antimicrobial Chemotherapy·Catia MarzoliniDavid Back
Sep 3, 2016·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Dana S ClutterRobert W Shafer
Nov 11, 2016·AIDS·Aysel GuelerUNKNOWN Swiss HIV Cohort Study, Swiss National Cohort
Feb 6, 2017·Expert Opinion on Pharmacotherapy·Katya C Corado, Eric S Daar
Mar 24, 2017·The Journal of Antimicrobial Chemotherapy·Cristina GervasoniDario Cattaneo
Jun 3, 2017·The Journal of Antimicrobial Chemotherapy·Hanni BartelsCatia Marzolini
Jun 18, 2017·Expert Opinion on Drug Safety·Vicente SorianoPablo Labarga
Jun 20, 2017·The Annals of Pharmacotherapy·Alice TsengElizabeth J Phillips
Jun 27, 2017·F1000Research·Eric S Daar
Sep 30, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Dario CattaneoCristina Gervasoni
Oct 11, 2017·The Lancet. HIV·Mark A BoydCharles F Gilks
Nov 7, 2017·Pharmacotherapy·Christopher McCoyUNKNOWN Society of Infectious Diseases Pharmacists
Dec 14, 2017·The Journal of Antimicrobial Chemotherapy·José MoltóBonaventura Clotet

❮ Previous
Next ❯

Citations

Aug 28, 2018·AIDS Research and Human Retroviruses·Kimberley BrownErkki Lathouwers
Apr 16, 2020·Pharmaceutics·Hannes LengauerZdenko Časar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.